Sara Al-Zubeidi
Director, Commercial Strategy Consulting Global Pricing and Market Access
Sara Al-Zubeidi is a Director with Clarivate based in London. Sara has 7+ years commercial strategy consulting experience in life sciences, specializing in global pricing and market access.
Sara leads teams for global P&MA engagements on behalf of pharmaceutical and biotechnology companies. Areas of expertise include pricing and access strategy, evidence generation for HTA submission, innovative agreement strategy, HTA landscape analysis, analogue assessments, value proposition/story development and payer objection handling/negotiation tactics. She also has extensive experience in commercial opportunity assessments, including indication and opportunity prioritization and patient flow assessments. Sara has deep expertise across a wide span of therapeutic areas with oncology, orphan/rare diseases, cardiology, renal and metabolic diseases as specialist areas of interest.
Prior to joining consulting, Sara worked in business development specifically for HEOR and Evidence Strategy teams.
Sara has a Master’s degree in Pharmacogenetics and Stratified Medicine at University College of London (UCL) and a BSc (Hons) in Medical Genetics from Queen Mary University of London.
Latest news
Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report
Anticipated advancements in weight loss, diabetes, oncology, rare conditions and protein degraders poised to reshape patient care LONDON, U.K, January 6, 2026 Clarivate Plc (NYSE: CLVT), a leading global provider…
Clarivate Library Innovation Awards Launch to Celebrate Global Library Excellence
Awards open to ELUNA, IGeLU and IUG members London, U.K. December 15, 2025: Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of the inaugural…